Inclusion of patients with reduced performance status (ECOG 2 or higher) in FDA registrational trials for renal cell carcinoma (RCC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ronit Juthani, Panah Parab, Kala Seetharaman
Institution: Saint Vincent Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407698093